Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries and also in other parts of the world. NAFLD encompasses a histological spectrum ranging from simple steatosis to steatohepatitis, advanced fibrosis and inflammatory changes. It frequently occurs with features of the metabolic syndrome including obesity, type 2 diabetes mellitus, dyslipidemia and hypertension. In fact, the metabolic syndrome is a strong predictor of NAFLD. Recently, Niemann-Pick C1-like 1 (NPC1L1) has been shown to play a pivotal role in cholesterol absorption. Unlike mouse NPC1L1 protein, predominantly expressed in the intestines, human and rat NPC1L1 is also abundantly expressed in the liver. Though the exact functions of hepatic NPC1L1 remain unknown, NPC1L1 may facilitate the hepatic accumulation of cholesterol. This raises a potential possibility that ezetimibe may improve fatty liver formation. In this review, potential role of lipid metabolism in NAFLD and its possible modulation through NPC1L1 blockade is discussed.
Keywords: NAFLD, NPC1L1, metabolic syndrome, insulin resistance, steatosis, steatohepa-titis, fibrosis, type 2 diabetes mellitus, dyslipidemia, hypertension, Niemann-Pick C1-like 1, adipogenic/lipogenic, alcoholic steatohepatitis (NASH), transcription factor PPAR, lipogenic factor SREBP, C/EBP, Ezetimibe, hepatocytes, tu-mor necrosis factor (TNF), lipopolysaccaride (LPS)-mediated steatosis, unfolded pro-tein response (UPR), splanchnic lipolysis, ZOF rats, Akt phosphorylation, gluconeogenic en-zymes (PEPCK and G6Pase), SREBP1c, ChREBP, FoxO1, CHOP, p38, methionine choline-deficient, TNF-alpha, SREBP2, HNF1
Current Vascular Pharmacology
Title: Novel Role of NPC1L1 in the Regulation of Hepatic Metabolism: Potential Contribution of Ezetimibe in NAFLD/NASH Treatment
Volume: 9 Issue: 1
Author(s): Masayuki Yoshida
Affiliation:
Keywords: NAFLD, NPC1L1, metabolic syndrome, insulin resistance, steatosis, steatohepa-titis, fibrosis, type 2 diabetes mellitus, dyslipidemia, hypertension, Niemann-Pick C1-like 1, adipogenic/lipogenic, alcoholic steatohepatitis (NASH), transcription factor PPAR, lipogenic factor SREBP, C/EBP, Ezetimibe, hepatocytes, tu-mor necrosis factor (TNF), lipopolysaccaride (LPS)-mediated steatosis, unfolded pro-tein response (UPR), splanchnic lipolysis, ZOF rats, Akt phosphorylation, gluconeogenic en-zymes (PEPCK and G6Pase), SREBP1c, ChREBP, FoxO1, CHOP, p38, methionine choline-deficient, TNF-alpha, SREBP2, HNF1
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries and also in other parts of the world. NAFLD encompasses a histological spectrum ranging from simple steatosis to steatohepatitis, advanced fibrosis and inflammatory changes. It frequently occurs with features of the metabolic syndrome including obesity, type 2 diabetes mellitus, dyslipidemia and hypertension. In fact, the metabolic syndrome is a strong predictor of NAFLD. Recently, Niemann-Pick C1-like 1 (NPC1L1) has been shown to play a pivotal role in cholesterol absorption. Unlike mouse NPC1L1 protein, predominantly expressed in the intestines, human and rat NPC1L1 is also abundantly expressed in the liver. Though the exact functions of hepatic NPC1L1 remain unknown, NPC1L1 may facilitate the hepatic accumulation of cholesterol. This raises a potential possibility that ezetimibe may improve fatty liver formation. In this review, potential role of lipid metabolism in NAFLD and its possible modulation through NPC1L1 blockade is discussed.
Export Options
About this article
Cite this article as:
Yoshida Masayuki, Novel Role of NPC1L1 in the Regulation of Hepatic Metabolism: Potential Contribution of Ezetimibe in NAFLD/NASH Treatment, Current Vascular Pharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157016111793744715
DOI https://dx.doi.org/10.2174/157016111793744715 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis
Vascular Disease Prevention (Discontinued) <i>In Silico</i> ADMET and Docking Studies of Thiazolidinedione-acetic-acid Hybrids as Antidiabetics with Cardioprotection
Letters in Drug Design & Discovery Prevalence of the Effects of Anxiety and Depression on People with Type 2 Diabetes Mellitus: An Analysis of Health Policy Studies in Improving the Quality of Life of Poor Families in the Urban Areas of West Lombok, Indonesia
Current Diabetes Reviews Withdrawal Notice: Design and optimization of piezoresistive based microbridge electro-osmosis pressure sensor
Micro and Nanosystems Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Hypoglycemic and Hypolipemic Effects of a New Lecithin Formulation of Bergamot Polyphenolic Fraction: A Double Blind, Randomized, Placebo- Controlled Study
Endocrine, Metabolic & Immune Disorders - Drug Targets The Burden of Cardiovascular Disease Risk Factors in the Middle East: A Systematic Review and Meta-Analysis Focusing on Primary Prevention
Current Vascular Pharmacology Antipsychotics in the Treatment of Impulsivity in Personality Disorders and Impulse Control Disorders
Current Psychopharmacology Development of Pyrazole Compounds as Antidiabetic Agent: A Review
Letters in Drug Design & Discovery Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Five Years Patenting Time Frame Concerning Enzymatic Preparation of Glycosides
Recent Patents on Biotechnology Biomarkers of Diabetic Nephropathy, the Present and the Future
Current Diabetes Reviews Chickpea (Cicer arietinum L.) Lectin Exhibit Inhibition of ACE-I, α-amylase and α-glucosidase Activity
Protein & Peptide Letters Efficacy of Dietary Supplementation with Botanicals on Carbohydrate Metabolism in Humans
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D and Vascular Disease
Current Vascular Pharmacology Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology Statins for Early Stage Chronic Kidney Disease: An Overview of Reviews
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery